Latest Market News

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Prairie Lithium has completed critical groundwork at its Canadian lithium brine project, setting the stage for construction and commercial operations in 2026 amid rising lithium prices.

Transurban Group has announced a 34.0 cents per stapled security interim distribution for the half-year ending December 2025, maintaining its FY26 distribution guidance at 69.0 cents. The Distribution Reinvestment Plan will operate without a discount, signaling steady confidence amid ongoing macroeconomic uncertainties.

Microba Life Sciences has secured a $3.06 million R&D tax incentive refund for FY25, reinforcing its cash reserves and supporting ongoing advancements in gastrointestinal diagnostics and clinical therapeutics.

Phoslock Environmental Technologies is set to resume production at its Changxing factory after a four-year halt, signaling renewed confidence in market demand and operational stability.

QuickFee Limited has completed a $28.5 million capital return following the sale of its US Pay Now and Connect businesses, while updating its dividend policy to target regular shareholder cash distributions starting in FY26.

Transurban Group has announced a 34-cent unfranked dividend per stapled security for the six months ending December 2025, alongside a Dividend Reinvestment Plan with no discount.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Control Bionics Limited is set to acquire the remaining stake in Neuro Elite Athletics, integrating the NeuroBounce athletic performance program with its EMG technology to accelerate growth in key markets.

BetMakers Technology Group has secured a favorable three-year content distribution agreement with Penn Entertainment, alongside strong digital customer growth that signals robust momentum for FY26 and beyond.

Transurban Group has announced a 34.0 cents per stapled security interim distribution for the half-year ending December 2025, reaffirming its full-year FY26 guidance of 69.0 cents. The Distribution Reinvestment Plan will proceed without a discount, signaling steady confidence amid ongoing market conditions.